Interstitial pneumonitis related to imatinib (Glivec) shows various radiological patterns but
usually improves after imatinib withdrawal or subsequent corticosteroid treatment (1-4) …

Imatinib is generally well tolerated, with mild common side effects such as nausea and
vomiting, diarrhea, muscle cramps, fatigue, skin rash and edema; however, pulmonary …

Imatinib mesylate (Gleevec, Glivec, formerly, STI571) is an inhibitor of the BCR-ABL tyrosine
kinase that is central to the pathogenesis of chronic myelogenous leukemia (CML). A recent …

The patient was a 64-year-old woman who had undergone partial enterectomy for a small
intestinal tumor in August 2005, and gastrointestinal stromal tumor (GIST) was diagnosed …

A 74-year-old man with idiopathic pulmonary fibrosis (IPF) developed severe dyspnea on
exertion after the readministration of imatinib mesylate for chronic myeloid leukemia. Chest …

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl
fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c …

We report 2 cases of successful reintroduction of mesylate imatinib for gastrointestinal
stromal tumor (GIST) after drug-induced pneumonitis. Both of them were women in the fifth …

Imatinib mesylate (IM) is a tyrosine kinase inhibitor that targets protein kinase, such as BCR-
ABL, KIT, and platelet derived growth factor receptor-A and B. The efficacy and safety of IM …

A 78-year-old Japanese woman with no history of pulmonary disease was diagnosed with
chronic myeloid leukaemia (CML) in chronic phase on 29 May 2002. After the WBC was …

Discussion Gastro-intestinal stromal tumours comprise a group of smooth muscle
mesenchymal alimentary tract tumours of variable malignancy. These mesenchymal …